Now showing items 1-20 of 21

    • Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. 

      Moreau, P; Dimopoulos, MA; Richardson, PG; Siegel, DS; Cavo, M; Corradini, P; Weisel, K; Delforge, M; O'Gorman, P; Song, K; Chen, C; Bahlis, N; Oriol, A; Hansson, M; Kaiser, M; Anttila, P; Raymakers, R; Joao, C; Cook, G; Sternas, L; Biyukov, T; Slaughter, A; Hong, K; Herring, J; Yu, X; Zaki, M; San-Miguel, J (2017-09)
      OBJECTIVES: Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough ...
    • Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. 

      Winfield, JM; Poillucci, G; Blackledge, MD; Collins, DJ; Shah, V; Tunariu, N; Kaiser, MF; Messiou, C (2018-04)
      OBJECTIVES: The aim of this study was to identify apparent diffusion coefficient (ADC) values for typical haemangiomas in the spine and to compare them with active malignant focal deposits. METHODS: This was a retrospective ...
    • Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. 

      Went, M; Sud, A; Law, PJ; Johnson, DC; Weinhold, N; Försti, A; van Duin, M; Mitchell, JS; Chen, B; Kuiper, R; Stephens, OW; Bertsch, U; Campo, C; Einsele, H; Gregory, WM; Henrion, M; Hillengass, J; Hoffmann, P; Jackson, GH; Lenive, O; Nickel, J; Nöthen, MM; da Silva Filho, MI; Thomsen, H; Walker, BA; Broyl, A; Davies, FE; Langer, C; Hansson, M; Kaiser, M; Sonneveld, P; Goldschmidt, H; Hemminki, K; Nilsson, B; Morgan, GJ; Houlston, RS (2017-06-16)
    • Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 

      Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; Kimber, S; van Duin, M; Thorleifsson, G; Holroyd, A; Johnson, DC; Li, N; Orlando, G; Law, PJ; Ali, M; Chen, B; Mitchell, JS; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Bandapalli, OR; Einsele, H; Gregory, WA; Gullberg, U; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Johnsson, E; Kristinsson, SY; Mellqvist, U-H; Nahi, H; Easton, D; Pharoah, P; Dunning, A; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Thomsen, H; Turesson, I; Vangsted, A; Andersen, NF; Waage, A; Walker, BA; Wihlborg, A-K; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Goldschmidt, H; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Hemminki, K; Nilsson, B; Houlston, RS (2019-01-10)
      The original version of this Article contained an error in the spelling of a member of the PRACTICAL Consortium, Manuela Gago-Dominguez, which was incorrectly given as Manuela Gago Dominguez. This has now been corrected ...
    • Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report. 

      Shah, V; Boyd, KD; Houlston, RS; Kaiser, MF (2017-11-06)
      BACKGROUND: Multiple Myeloma is a cancer of plasma cells associated with significantly reduced survival. Long term survivorship from myeloma is very rare and despite advances in its treatment the disease is generally ...
    • The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. 

      Sriskandarajah, P; Pawlyn, C; Mohammed, K; Dearden, CE; Davies, FE; Morgan, GJ; Boyd, KD; Kaiser, MF (2016-07-20)
    • Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. 

      Went, M; Sud, A; Speedy, H; Sunter, NJ; Försti, A; Law, PJ; Johnson, DC; Mirabella, F; Holroyd, A; Li, N; Orlando, G; Weinhold, N; van Duin, M; Chen, B; Mitchell, JS; Mansouri, L; Juliusson, G; Smedby, KE; Jayne, S; Majid, A; Dearden, C; Allsup, DJ; Bailey, JR; Pratt, G; Pepper, C; Fegan, C; Rosenquist, R; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Einsele, H; Gregory, WM; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Nickel, J; Nöthen, MM; da Silva Filho, MI; Thomsen, H; Walker, BA; Broyl, A; Davies, FE; Hansson, M; Goldschmidt, H; Dyer, MJS; Kaiser, M; Sonneveld, P; Morgan, GJ; Hemminki, K; Nilsson, B; Catovsky, D; Allan, JM; Houlston, RS (2018-12-21)
      The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma ...
    • Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. 

      Li, N; Johnson, DC; Weinhold, N; Kimber, S; Dobbins, SE; Mitchell, JS; Kinnersley, B; Sud, A; Law, PJ; Orlando, G; Scales, M; Wardell, CP; Försti, A; Hoang, PH; Went, M; Holroyd, A; Hariri, F; Pastinen, T; Meissner, T; Goldschmidt, H; Hemminki, K; Morgan, GJ; Kaiser, M; Houlston, RS (2017-09-12)
      Multiple myeloma (MM) is a malignancy of plasma cells. Genome-wide association studies have shown that variation at 5q15 influences MM risk. Here, we have sought to decipher the causal variant at 5q15 and the mechanism by ...
    • Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. 

      Law, PJ; Sud, A; Mitchell, JS; Henrion, M; Orlando, G; Lenive, O; Broderick, P; Speedy, HE; Johnson, DC; Kaiser, M; Weinhold, N; Cooke, R; Sunter, NJ; Jackson, GH; Summerfield, G; Harris, RJ; Pettitt, AR; Allsup, DJ; Carmichael, J; Bailey, JR; Pratt, G; Rahman, T; Pepper, C; Fegan, C; von Strandmann, EP; Engert, A; Försti, A; Chen, B; Filho, MIDS; Thomsen, H; Hoffmann, P; Noethen, MM; Eisele, L; Jöckel, K-H; Allan, JM; Swerdlow, AJ; Goldschmidt, H; Catovsky, D; Morgan, GJ; Hemminki, K; Houlston, RS (2017-01-23)
      B-cell malignancies (BCM) originate from the same cell of origin, but at different maturation stages and have distinct clinical phenotypes. Although genetic risk variants for individual BCMs have been identified, an agnostic, ...
    • Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. 

      Mitchell, JS; Li, N; Weinhold, N; Försti, A; Ali, M; van Duin, M; Thorleifsson, G; Johnson, DC; Chen, B; Halvarsson, BM; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Einsele, H; Gregory, WA; Gullberg, U; Henrion, M; Hillengass, J; Hoffmann, P; Jackson, GH; Johnsson, E; Jöud, M; Kristinsson, SY; Lenhoff, S; Lenive, O; Mellqvist, UH; Migliorini, G; Nahi, H; Nelander, S; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Swaminathan, B; Thomsen, H; Turesson, I; Vangsted, A; Vogel, U; Waage, A; Walker, BA; Wihlborg, AK; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Goldschmidt, H; Hemminki, K; Nilsson, B; Houlston, RS (2016-01)
      Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-wide association studies have transformed our understanding of MM predisposition, but individual studies have had limited power ...
    • The genomic landscape of plasma cells in systemic light chain amyloidosis. 

      Boyle, EM; Ashby, C; Wardell, CP; Rowczenio, D; Sachchithanantham, S; Wang, Y; Johnson, SK; Bauer, MA; Weinhold, N; Kaiser, MF; Johnson, DC; Jones, JR; Pawlyn, C; Proszek, P; Schinke, C; Facon, T; Dumontet, C; Davies, FE; Morgan, GJ; Walker, BA; Wechalekar, AD (2018-12-27)
    • Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 

      Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; Kimber, S; van Duin, M; Thorleifsson, G; Holroyd, A; Johnson, DC; Li, N; Orlando, G; Law, PJ; Ali, M; Chen, B; Mitchell, JS; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Bandapalli, OR; Einsele, H; Gregory, WA; Gullberg, U; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Johnsson, E; Kristinsson, SY; Mellqvist, U-H; Nahi, H; Easton, D; Pharoah, P; Dunning, A; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Thomsen, H; Turesson, I; Vangsted, A; Andersen, NF; Waage, A; Walker, BA; Wihlborg, A-K; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Goldschmidt, H; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Hemminki, K; Nilsson, B; Houlston, RS; PRACTICAL consortium (2018-09-13)
      Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ...
    • Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. 

      Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; Hockaday, A; Jones, JR; Kishore, B; Garg, M; Williams, CD; Karunanithi, K; Lindsay, J; Jenner, MW; Cook, G; Russell, NH; Kaiser, MF; Drayson, MT; Owen, RG; Gregory, WM; Morgan, GJ; UK NCRI Haemato-oncology Clinical Studies Group (2019-01)
      BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide ...
    • A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. 

      Bødker, JS; Brøndum, RF; Schmitz, A; Schönherz, AA; Jespersen, DS; Sønderkær, M; Vesteghem, C; Due, H; Nørgaard, CH; Perez-Andres, M; Samur, MK; Davies, F; Walker, B; Pawlyn, C; Kaiser, M; Johnson, D; Bertsch, U; Broyl, A; van Duin, M; Shah, R; Johansen, P; Nørgaard, MA; Samworth, RJ; Sonneveld, P; Goldschmidt, H; Morgan, GJ; Orfao, A; Munshi, N; Johnson, HE; El-Galaly, T; Dybkær, K; Bøgsted, M (2018-09-25)
      Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and ...
    • Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. 

      Li, N; Johnson, DC; Weinhold, N; Studd, JB; Orlando, G; Mirabella, F; Mitchell, JS; Meissner, T; Kaiser, M; Goldschmidt, H; Hemminki, K; Morgan, GJ; Houlston, RS (2016-11-24)
      Genome-wide association studies have identified several risk loci for multiple myeloma (MM); however, the mechanisms by which they influence MM are unknown. Here by using genetic association data and functional characterization, ...
    • Neutral tumor evolution in myeloma is associated with poor prognosis. 

      Johnson, DC; Lenive, O; Mitchell, J; Jackson, G; Owen, R; Drayson, M; Cook, G; Jones, JR; Pawlyn, C; Davies, FE; Walker, BA; Wardell, C; Gregory, WM; Cairns, D; Morgan, GJ; Houlston, RS; Kaiser, MF (2017-10-05)
      Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, ...
    • Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. 

      Pawlyn, C; Bright, MD; Buros, AF; Stein, CK; Walters, Z; Aronson, LI; Mirabella, F; Jones, JR; Kaiser, MF; Walker, BA; Jackson, GH; Clarke, PA; Bergsagel, PL; Workman, P; Chesi, M; Morgan, GJ; Davies, FE (2017-03-31)
      Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly ...
    • Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. 

      Dimopoulos, MA; Palumbo, A; Corradini, P; Cavo, M; Delforge, M; Di Raimondo, F; Weisel, KC; Oriol, A; Hansson, M; Vacca, A; Blanchard, MJ; Goldschmidt, H; Doyen, C; Kaiser, M; Petrini, M; Anttila, P; Cafro, AM; Raymakers, R; San-Miguel, J; de Arriba, F; Knop, S; Röllig, C; Ocio, EM; Morgan, G; Miller, N; Simcock, M; Peluso, T; Herring, J; Sternas, L; Zaki, MH; Moreau, P (2016-07)
      Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients ...
    • Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. 

      Jones, JR; Cairns, DA; Gregory, WM; Collett, C; Pawlyn, C; Sigsworth, R; Striha, A; Henderson, R; Kaiser, MF; Jenner, M; Cook, G; Russell, NH; Williams, C; Pratt, G; Kishore, B; Lindsay, J; Drayson, MT; Davies, FE; Boyd, KD; Owen, RG; Jackson, GH; Morgan, GJ (2016-12-09)
      We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary ...
    • The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. 

      Pawlyn, C; Kaiser, MF; Heuck, C; Melchor, L; Wardell, CP; Murison, A; Chavan, SS; Johnson, DC; Begum, DB; Dahir, NM; Proszek, PZ; Cairns, DA; Boyle, EM; Jones, JR; Cook, G; Drayson, MT; Owen, RG; Gregory, WM; Jackson, GH; Barlogie, B; Davies, FE; Walker, BA; Morgan, GJ (2016-12-01)
      PURPOSE: Epigenetic dysregulation is known to be an important contributor to myeloma pathogenesis but, unlike other B-cell malignancies, the full spectrum of somatic mutations in epigenetic modifiers has not been reported ...